tiprankstipranks
Revive Therapeutics Advances Long COVID Treatment
Company Announcements

Revive Therapeutics Advances Long COVID Treatment

Revive Therapeutics (TSE:RVV) has released an update.

Pick the best stocks and maximize your portfolio:

Revive Therapeutics Ltd. has announced positive feedback from the FDA regarding the development of Bucillamine, a drug with anti-inflammatory and antiviral properties, as a potential treatment for Long COVID. The FDA has advised the company to file a new IND application for Bucillamine, using data from their Phase 3 trial on mild to moderate COVID-19, to support their upcoming clinical trial for Long COVID. This comes as the company leverages previous research and aims to address the estimated 7.5% of U.S. adults suffering from Long COVID symptoms.

For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyRevive Therapeutics announces publication on potential of psilocybin
TipRanks Canadian Auto-Generated NewsdeskRevive Therapeutics Explores Psilocybin for Stroke Treatment
TheFlyRevive Therapeutics provides update on research study of bucillamine
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App